search

Active clinical trials for "Lymphoma, Large B-Cell, Diffuse"

Results 1141-1150 of 1161

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

This is a prospective observational study. The primary objective is to identify new prognostic biomarkers for DLBCL patients in terms of progression-free survival (PFS) and able to add predictive capacity to recognized important clinical factors. The secondary objectives are: to identify new biomarkers associated with overall survival (OS) and objective response rate (ORR) to characterize tissue and circulating immune microenvironment of DLBCL patients by bulk and single cell transcriptomics; to assess the correlation between the expression of immune checkpoint genes and mRNA signature; to describe the mutational status of a panel of genes relevant to DLBCL pathogenesis;. to assess the correlation between protein expression, mutational status and the messenger RNA (mRNA) signature. For each enrolled patient, immunohistochemical determinations will be performed: Cell of origin (COO) (Germinal Cell -GC- or activated B-cell - ABC- type according with Hans algorithm ), evaluation of cluster of differentiation antigen 20 (CD20), cluster of differentiation antigen 5 (CD5), cluster of differentiation antigen 10 (CD10), Bcl6, Bcl2 (cut off>50%), Multiple Myeloma 1 / Interferon Regulatory Factor 4 protein (MUM1/IRF4), c-myc (cut off>40%) and Ki67, fluorescence in situ hybridization (FISH) for c-myc and if rearranged, for Bcl2 e Bcl6 ). Moreover, paraffin embedded (FFPE) tumor specimens will be collected for RNA extraction and mRNA expression analysis and sent to Bioscience Laboratory of Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST-IRCCS).

Unknown status3 enrollment criteria

Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell...

LymphomaLarge B-Cell1 more

This study will evaluate IgNGS at different time points in newly diagnosed DLBCL patients homogeneously treated (RCHOP) to address its correlation with conventional techniques (i.e., positron emission tomography/computed tomography imaging (PET/CT) and outcome.

Unknown status5 enrollment criteria

A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab...

Diffuse Large B-Cell Lymphoma (DLBCL)

To assess the clinical outcomes following treatment with Pola in combination with Bendamustine, Rituximab (BR) or Rituximab (R) in patients with R/R DLBCL who are not eligible for transplantation in the real-world setting.

Unknown status7 enrollment criteria

HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life

Breast Cancer FemaleBreast Neoplasm18 more

The purpose of this study is to invite all people diagnosed with cancer who meet the eligibility criteria to complete questionnaires before their treatment begins and at regular intervals over time to assess the impact of cancer and its treatment on people's lives in the short, medium and long term. We will explore a range of factors to determine their role in both recovery of health and well-being and self-management. Although it is known that people who have had cancer are likely to experience a number of physical and psychological problems as a result of the disease and treatment, it is not known what the 'typical' course of recovery of health and well-being looks like, how long it takes and how this can be influenced. We will determine pathways to recovery of health and well-being following cancer diagnosis (initially breast cancer diagnosed <50 years, Non-Hodgkin Lymphoma and gynaecological cancers) and identify what factors influence this. This includes assessing the relative importance of the person's illness, personal attributes, perceived burden of treatment, role of the environment they live in, including health / social care and personal networks of support, and their ability and capacity to self-manage. We will identify who is most at risk of problems and what environmental supports and resources people are able to mobilise to support their self-management. We will also explore who has the confidence and ability to manage during and beyond treatment and what factors influence this and whether this leads to earlier problem resolution and restoration of health and well-being. This knowledge will be used to develop and test future supportive interventions to enhance the rapid recovery of health and well-being - our long term aim being to design ways of helping people with cancer in areas we identify as problematic for them.

Unknown status75 enrollment criteria

Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM...

LymphomaLarge B-Cell1 more

Prospective data collection of a consecutive series of elderly patients with large B-cell lymphoma newly diagnosed, receiving before the start of treatment Multidimensional Geriatric Assessment (VGM) through the use of Activity of Daily Living (ADL), Instrumental Activity of Daily Living (IADL) and Cumulative Illness Rating Scale for Geriatrics (CIRS-G).

Unknown status6 enrollment criteria

Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression...

LymphomaLarge B-Cell1 more

DLBCL has the highest frequency out of all lymphoid malignancies. With the recent development of antitumor agents targeting intracellular/extracellular cell signaling pathways, patients have access to various treatment options after relapse. Therefore, for the purpose of developing effective treatment strategies, large-scale genomic data accumulation is necessary to understand the mechanism of relapse and refractory state of DLBCL.

Unknown status17 enrollment criteria

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

Diffuse Large B Cell Lymphoma

This study is to evaluate the efficacy related molecular biomarker of Lenalidomide plus RCHOP or RICE in the treatment of de novo or Refractory and Relapsed DLBCL patients

Unknown status11 enrollment criteria

A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients

Diffuse Large B-cell Lymphoma

This is a prospective , open, multicenter, randomized phase Ⅲ study. The investigators planed to include 732 untreated CD20 positive diffused large B cell lymphoma adults,to random to R-CHOP21, CHOP14 , R-CHOP14 regimen groups after signature the informed consents. The patients will receive safety assessment every cycles, and efficacy evaluation every 2 cycles. Every-two-months follow up will be received after finishing the treatment.

Unknown status25 enrollment criteria

The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas

Lymphoma,Non-HodgkinDiffuse Large B Cell Lymphoma1 more

The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.

Unknown status6 enrollment criteria

Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients...

Diffuse Large B Cell LymphomaPeripheral T Cell Lymphoma

The purpose of this study is to evaluate the effectiveness of circulating DNA from peripheral blood for predicting the prognosis and relapse in DLBCL and PTCL patients.

Unknown status6 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs